Airway and Lung Infection
An Introduction to Airway and Lung Infection
The field of airway and lung infection is topical in the wake of the COVID-19 pandemic; SARS-CoV-2 is one of several novel respiratory viruses to emerge in the 21st century. Viruses and bacteria can cause a range of respiratory diseases, including acute bronchitis, the common cold, influenza, respiratory distress syndromes, pertussis, pneumonia and tuberculosis. Symptoms of viral infections may range from being very mild to a severe respiratory illness, and therefore prompt and reliable diagnosis is essential. Antibiotic resistance remains the major challenge in bacterial infection. Emerging approaches include cell-based therapies involving mesenchymal stem cells in the treatment of respiratory infections. However, the multiple challenges involved in developing curative therapies for infections highlight the importance of prevention, and vaccine research is essential.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Airway and Lung Infection Content
Management of patients with NTM-LD: Improving adherence for optimal outcomes
Watch expert pulmonologists discuss how to optimize the diagnosis and management of patients with NTM-LD
- Appraise strategies to reduce time to diagnosis for patients with NTM-LD
- Utilize guideline recommendations when setting individualized treatment goals for patients with NTM-LD
- Apply strategies to manage adverse events for improved outcomes and adherence in patients with NTM-LD
The patient pathway to diagnosis for non-cystic fibrosis bronchiectasis
MDT specialists and a patient with non-cystic fibrosis (non-CF) bronchiectasis discuss the pathophysiology, comorbidities and the pathway to diagnosis
- Describe the pathophysiology and comorbidities of non-CF bronchiectasis
- Appraise the clinical presentations of non-CF bronchiectasis
- Analyse the methodologies to diagnose non-CF bronchiectasis
Cytomegalovirus in solid organ transplant recipients: Management strategies and emerging therapeutic options
Watch experts give their perspectives on management challenges, antiviral options and best practice in treating cytomegalovirus in solid organ transplant recipients.
- Explain the unmet needs of solid organ transplant recipients susceptible to cytomegalovirus (CMV)
- Discuss evolving antiviral options for solid organ transplant recipients with resistant or refractory (R/R) CMV
- Summarize best practice for the management of R/R CMV in solid organ transplant recipients
Steven Shapiro: FDA Approval of a Pneumococcal 15-valent Conjugate Vaccine for Invasive Pneumococcal Disease in Children
Following the FDA approval of a pneumococcal 15-valent conjugate vaccine (Vaxneuvance) for the prevention of invasive disease caused by Streptococcus pneumoniae in children, we were delighted to speak with Dr. Steven Shapiro (Jefferson Abington Hospital, Abington, PA, USA) to discuss the unmet needs, the clinical data supporting the approval, and the impact approval will have on preventing invasive pneumococcal disease. […]
NTM lung disease: a serious problem we should always be aware of
Watch Prof. Stefano Aliberti discuss the impact of Nontuberculosis mycobacteria (NTM) lung disease on patients and how to improve awareness and increase detection of the condition.
COVID-19-induced Lung Fibrosis
touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(1):6–7
Coronavirus is a family of enveloped RNA viruses that include the original SARS coronavirus (SARS-CoV) and the recently emerged SARS-CoV-2. According to the World Health Organization, there have been over 500 million confirmed SARS-CoV-2 infections, and well over 6 million deaths from coronavirus disease 2019 (COVID-19).1 Although the recovery rate from COVID-19 is estimated to be […]
Current and future best practice for the management of non-cystic fibrosis bronchiectasis
Experts discuss best practice management options for patients with non-cystic fibrosis bronchiectasis.
- Review the incidence, causes and risk factors for non-cystic fibrosis bronchiectasis
- Discuss eradication protocols for infection in patients with non-cystic fibrosis bronchiectasis
- Evaluate available and emerging pharmacotherapeutic treatments for non-cystic fibrosis bronchiectasis
Implementing optimal stewardship strategies to combat antibiotic resistance
Leading infection control experts explore multidisciplinary strategies for antimicrobial stewardship and new and emerging agents to combat multidrug-resistant microbes.
- Analyse the importance of a multidisciplinary approach to patient care in the management of antibiotic resistance
- Evaluate how current guidelines direct individualized patient care for antibiotic-resistant infections
- Discuss the practical use of new and emerging management options for antibiotic-resistant infections
Recent Advances in Primary Ciliary Dyskinesia: From Diagnosis to Treatment
touchREVIEWS in Respiratory & Pulmonary Diseases. 2021;6(1):14–20 DOI: https://doi.org/10.17925/USPRD.2021.6.1.14
Primary ciliary dyskinesia (PCD), previously known as immotile cilia syndrome, is a rare genetic disease characterized by abnormal ciliary function due to defects in the structure and/or function of motile cilia, leading to recurrent and chronic infections of the upper and lower airways as a result of impaired mucociliary clearance.1 PCD is predominantly inherited in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!